Flagship record · Exenatide

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

human primarycontrolled human primarycomparator

Scientific attribution

The published source title identifies the governed peptide as the comparator.

PMID: 29246950
DOI: 10.2337/dc17-0417
Sample size: 813
Population / model: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.

Intervention / comparator

Mean HbA 1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] -0.62% [95% CI -0.80, -0.44] [-6.78 mmol/mol (95% CI -8.70, -4.86)]; P P 1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%).

Outcomes

The primary end point was change from baseline in HbA 1c at week 56.
Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles.

Key findings

Mean HbA 1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] -0.62% [95% CI -0.80, -0.44] [-6.78 mmol/mol (95% CI -8.70, -4.86)]; P P 1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%).
These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.